Kazuyuki Numakura

List of Publications by Year
in descending order

50	592	840776 11	713466 21
papers	citations	h-index	g-index

54	54	54	783
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Effect of HLA genotype on intravesical recurrence after bacillus Calmetteâ€“GuÃ©rin therapy for non-muscle-invasive bladder cancer. Cancer Immunology, Immunotherapy, 2022, 71, 727-736.	4.2	9
2	Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma. BJUI Compass, 2022, 3, 154-161.	1.3	13
3	Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era â€“ a multi-institutional retrospective study. International Journal of Clinical Oncology, 2022, 27, 563.	2.2	5
4	Overview of clinical management for older patients with renal cell carcinoma. Japanese Journal of Clinical Oncology, 2022, 52, 665-681.	1.3	2
5	Specific Gut Microbial Environment in Lard Diet-Induced Prostate Cancer Development and Progression. International Journal of Molecular Sciences, 2022, 23, 2214.	4.1	3
6	Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism. Genes, 2022, 13, 1204.	2.4	7
7	Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study. International Journal of Clinical Oncology, 2021, 26, 154-162.	2.2	11
8	Impact of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma receiving systemic tyrosine kinase inhibitor therapy: A multicenter retrospective study. International Journal of Urology, 2021, 28, 369-375.	1.0	10
9	Efficacy and safety of subsequent molecular targeted therapy after immuno-checkpoint therapy, retrospective study of Japanese patients with metastatic renal cell carcinoma (AFTER I-O study). Japanese Journal of Clinical Oncology, 2021, 51, 966-975.	1.3	12
10	Outcomes of axitinib versus sunitinib as firstâ€line therapy to patients with metastatic renal cell carcinoma in the immuneâ€oncology era. Cancer Medicine, 2021, 10, 5839-5846.	2.8	10
11	Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma. Japanese Journal of Clinical Oncology, 2021, 51, 1656-1664.	1.3	7
12	External validation of the REMARCC model for the selection of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma: A multicenter retrospective study. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 836.e11-836.e17.	1.6	4
13	Incidence, Etiology, Prevention and Management of Ureteroenteric Strictures after Robot-Assisted Radical Cystectomy: A Review of Published Evidence and Personal Experience. Current Oncology, 2021, 28, 4109-4117.	2.2	8
14	Robotic-assisted laparoscopic partial nephrectomy for renal cell carcinoma in horseshoe kidney: a hybrid technique with conventional laparoscopic surgery. International Cancer Conference Journal, 2020, 9, 199-202.	0.5	3
15	First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology. Scientific Reports, 2020, 10, 20089.	3.3	2
16	Prognostic value of plasminogen activator inhibitorâ€1 in biomarker exploration using multiplex immunoassay in patients with metastatic renal cell carcinoma treated with axitinib. Health Science Reports, 2020, 3, e197.	1.5	0
17	Efficacy and safety of firstâ€line nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma: A multicenter retrospective study. International Journal of Urology, 2020, 27, 1095-1100.	1.0	20
18	Acute kidney injury and its impact on renal prognosis after robotâ€assisted laparoscopic radical prostatectomy. International Journal of Medical Robotics and Computer Assisted Surgery, 2020, 16, 1-7.	2.3	5

#	Article	IF	Citations
19	Efficacy and safety of nivolumab for renal cell carcinoma in patients over 75Âyears old from multiple Japanese institutes. International Journal of Clinical Oncology, 2020, 25, 1543-1550.	2.2	10
20	Changes in PCSK9 and LDL cholesterol concentrations by everolimus treatment and their effects on polymorphisms in PCSK9 and mTORC1. Pharmacological Reports, 2020, 72, 622-630.	3.3	5
21	Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101. Cancer Science, 2020, 111, 907-923.	3.9	33
22	Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer. BMC Cancer, 2020, 20, 302.	2.6	10
23	Treatment-free survival after discontinuation of immuno-checkpoint therapy, and outcome of subsequent molecular targeted therapy: Retrospective study of Japanese metastatic renal cell carcinoma patients (after I-O study).. Journal of Clinical Oncology, 2020, 38, 677-677.	1.6	0
24	Validation of the IMDC Prognostic Model in Patients With Metastatic Renal-Cell Carcinoma Treated With First-Line Axitinib: A Multicenter Retrospective Study. Clinical Genitourinary Cancer, 2019, 17, e1080-e1089.	1.9	10
25	Efficacy of antiâ€'PDâ€'1 antibody nivolumab in Japanese patients with metastatic renal cell carcinoma: A retrospective multicenter analysis. Molecular and Clinical Oncology, 2019, 11, 320-324.	1.0	12
26	Impact of persistent preformed and de novo donor-specific antibodies detected at 1Âyear after kidney transplantation on long-term graft survival in Japan: a retrospective study. Clinical and Experimental Nephrology, 2019, 23, 1398-1406.	1.6	4
27	Association of immunosuppressive agents and cytomegalovirus infection with de novo donor-specific antibody development within 1 year after renal transplantation. International Immunopharmacology, 2019, 76, 105881.	3.8	4
28	Radical Prostatectomy With and Without Neoadjuvant Chemohormonal Pretreatment for High-Risk Localized Prostate Cancer: A Comparative Propensity Score Matched Analysis. Clinical Genitourinary Cancer, 2019, 17, e113-e122.	1.9	14
29	Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma. Medical Oncology, 2018, 35, 51.	2.5	18
30	Influence of CYP3A5 genetic differences in tacrolimus on quantitative interstitial fibrosis and long-term graft function in kidney transplant recipients. International Immunopharmacology, 2018, 58, 57-63.	3.8	9
31	Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients. Oncotarget, 2018, 9, 25277-25284.	1.8	18
32	Incidence and location of positive surgical margin among open, laparoscopic and robot-assisted radical prostatectomy in prostate cancer patients: a single institutional analysis. Japanese Journal of Clinical Oncology, 2018, 48, 765-770.	1.3	22
33	Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients. International Journal of Molecular Sciences, 2018, 19, 882.	4.1	9
34	Impact of early changes in serum biomarkers following androgen deprivation therapy on clinical outcomes in metastatic hormone-sensitive prostate cancer. BMC Urology, 2018, 18, 32.	1.4	10
35	Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations. Clinical and Experimental Nephrology, 2017, 21, 787-796.	1.6	6
36	Clinical effects of single nucleotide polymorphisms on drug-related genes in Japanese metastatic renal cell carcinoma patients treated with sunitinib. Anti-Cancer Drugs, 2017, 28, 97-103.	1.4	14

#	Article	IF	Citations
37	Effect of hepatic drug transporter polymorphisms on the pharmacokinetics of mycophenolic acid in patients with severe renal dysfunction before renal transplantation. Xenobiotica, 2017, 47, 916-922.	1.1	12
38	The impact of UGT1A1 and SLCO1B1 genetic polymorphisms and pharmacokinetics of axitinib on clinical safety and efficacy in patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2017, 35, 448-448.	1.6	0
39	Impact of obesity and adiponectin signaling in patients with renal cell carcinoma: A potential mechanism for the obesity paradox.. Journal of Clinical Oncology, 2017, 35, 449-449.	1.6	2
40	Editorial Comment from Dr Numakura to Clinicopathological characteristics of Xp11.2 translocation renal cell carcinoma in adolescents and adults: Diagnosis using immunostaining of transcription factor E3 and fluorescence in situ hybridization analysis. International Journal of Urology, 2016, 23, 147-147.	1.0	0
41	Secondary bladder amyloidosis with familial Mediterranean fever in a living donor kidney transplant recipient: a case report. BMC Research Notes, 2016, 9, 473.	1.4	3
42	Influence of everolimus on the pharmacokinetics of tacrolimus in Japanese renal transplant patients. International Journal of Urology, 2016, 23, 484-490.	1.0	5
43	Capability of Utilizing CYP3A5 Polymorphisms to Predict Therapeutic Dosage of Tacrolimus at Early Stage Post-Renal Transplantation. International Journal of Molecular Sciences, 2015, 16, 1840-1854.	4.1	11
44	Pharmacokinetic and CYP3A5 pharmacogenetic differences between once- and twice-daily tacrolimus from the first dosing day to 1 year after renal transplantation. Pharmacogenomics, 2014, 15, 1495-1506.	1.3	11
45	Renal Subcapsular Fluid Collection Caused by Penetration of a Pancreatic Pseudocyst. Urology, 2014, 84, e23-e24.	1.0	1
46	Successful Local Control of Recurrent Penile Cancer Treated with a Combination of Systemic Chemotherapy, Irradiation, and Mohs' Paste: A Case Report. Case Reports in Oncology, 2014, 7, 522-527.	0.7	6
47	Pharmaceutical and genetic determinants for interindividual differences of tacrolimus bioavailability in renal transplant recipients. European Journal of Clinical Pharmacology, 2013, 69, 1659-1665.	1.9	26
48	Hyperuricemia at 1 Year After Renal Transplantation, Its Prevalence, Associated Factors, and Graft Survival. Transplantation, 2012, 94, 145-151.	1.0	36
49	Comparison of Pharmacokinetics and Pharmacogenetics of Once- and Twice-Daily Tacrolimus in the Early Stage After Renal Transplantation. Transplantation, 2012, 94, 1013-1019.	1.0	55
50	Clinical and Genetic Risk Factors for Posttransplant Diabetes Mellitus in Adult Renal Transplant Recipients Treated with Tacrolimus. Transplantation, 2005, 80, 1419-1424.	1.0	82